Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2

Conditions

Leukemia, Myeloid, Acute 36Advanced Solid Tumors 20Myelodysplastic Syndromes 14Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 13Advanced Solid Tumor 13Recurrence 10Ovarian Neoplasms 8Neoplasms 8Multiple Myeloma 8Leukemia, Myelomonocytic, Chronic 8Triple Negative Breast Neoplasms 7Solid Tumor 6Myeloproliferative Disorders 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Carcinoma, Hepatocellular 5Advanced Solid Tumour 5Sarcoma 4Melanoma 4Lymphoma, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Advanced Malignant Solid Tumor 4Advanced Lung Cancer 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

Cyclophosphamide 15fludarabine phosphate 11fludarabine 11Whole-Body Irradiation 11Mycophenolic Acid 11Busulfan 9Melphalan 8Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Azacitidine 5Filgrastim 4venetoclax 3Cord Blood Stem Cell Transplantation 3Biopsy 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Thiotepa 2Specimen Handling 2Sirolimus 2Rituximab 2Methotrexate 2Injections 2Hematopoietic Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporins 2Clofarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × Injections × 1 year × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

NCT07347171 2026-01-16

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

Cullgen (Shanghai),Inc

Phase 1 Recruiting
45 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡